mbiomics

mbiomicsmbiomics
mbiomics

mbiomics

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Website
DR 92020ActiveMunich, Germany
Rate
Advertise here

About

mbiomics designs and develops complex Live Biotherapeutic Products (LBPs) to change the treatment paradigm of severe and chronic diseases. They leverage proprietary precision analytics and patient insights to build a pipeline of rationally selected microbial communities for indication-specific treatment. Their goal is to access the gut microbiome's full immunological and metabolic potential to restore healthy microbial ecosystems and overcome disease.
Frequently asked

What does mbiomics do?

mbiomics designs and develops complex Live Biotherapeutic Products (LBPs) to change the treatment paradigm of severe and chronic diseases. They leverage proprietary precision analytics and patient insights to build a pipeline of rationally selected microbial communities for indication-specific treatment. Their goal is to access the gut microbiome's full immunological and metabolic potential to restore healthy microbial ecosystems and overcome disease.

What is mbiomics's revenue?

StartupHub estimates mbiomics's annual revenue at $1.5M (range $520K to $4.6M, 34% confidence), based on comparable companies in the sector.

What is mbiomics's valuation?

StartupHub estimates mbiomics's effective valuation at $47.5M (range $30.0M to $72.0M, 23% confidence), based on comparable companies in the sector.

How much funding has mbiomics raised?

mbiomics has raised a total of $12M in funding. The most recent round on record is Series A.

Where is mbiomics headquartered?

mbiomics is headquartered in Munich, Bavaria, Germany.

When was mbiomics founded?

mbiomics was founded in 2020.

What industry does mbiomics operate in?

mbiomics operates in Biotechnology, Pharmaceuticals, Healthcare, Artificial Intelligence, Biotech, MedTech.

Comments

No comments yet. Be the first to share your take.